Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | ADK | P55263 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722191 | 0.83 | NISCH (0.78) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL3399083 | 0.83 | KIF11 (0.54) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL862114 | 0.81 | NISCH (0.75) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL1719475 | 0.81 | NISCH (0.47) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL12632136 | 0.81 | NISCH (0.63) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL1719134 | 0.79 | MRGPRX4 (0.58) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL771236 | 0.78 | NISCH (0.64) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL4659327 | 0.77 | TOP1 (0.42) | KDM4EALDH1A1KIF11MRGPRX4ATM | |
| SCHEMBL1688472 | 0.77 | NISCH (0.68) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL1719845 | 0.77 | NISCH (0.49) | NISCHMTORADKKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113745539-B | Fluorine-containing non-noble metal oxygen reduction electrocatalyst and preparation method and application thereof | 大连理工大学 | 2022-11-22 | — | — | CN | claimed |
| CN-113745539-A | Fluorine-containing non-noble metal oxygen reduction electrocatalyst and preparation method and application thereof | 大连理工大学 | 2021-12-03 | — | — | CN | claimed |
| CN-107835814-B | Azabenzimidazoles and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| JP-2002541077-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1169005-A2 | ASSOCIATION OF NO-SYNTHASE INHIBITOR(S) AND METABOLIC ANTIOXIDANT(S) | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-09 | — | — | EP | claimed |
| WO-2000059448-A2 | ASSOCIATION OF NO-SYNTHASE INHIBITOR(S) AND METABOLIC ANTIOXIDANT(S) | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-10-12 | — | — | WO | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240417383-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2024-12-19 | — | — | US | disclosed |
| CN-113024467-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-3770146-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ASTELLAS ENG SMALL MOLECULES US INCORPORATED (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-113004205-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| US-20050234239-A1 | Method of forming a carbon-carbon or carbon-heteroatom linkage | SHASUN PHARMA SOLUTIONS, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030236413-A1 | Catalysis in presence of a metallic element, an imine ligand and nitrogen compound as chelating compound, forming a chemical intermediates in the agrochemical and pharmaceutical fields | SHASUN PHARMA SOLUTIONS, INC. | 2003-12-25 | — | — | US | disclosed |
| EP-1337516-A1 | PROCESS FOR MANUFACTURE OF IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040454-A1 | PROCESS FOR MANUFACTURE OF IMIDAZOLES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2001057038-A9 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS | BASF AG (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
| US-20050234239-A1 | Method of forming a carbon-carbon or carbon-heteroatom linkage | AOC1, AOC3, NUDT1 | NISCH 53/4885MTOR 4043/4885ADK 2247/4885 |
| US-20030236413-A1 | Catalysis in presence of a metallic element, an imine ligand and nitrogen compound as chelating compound, forming a chemical intermediates in the agrochemical and pharmaceutical fields | ALK, INMT, ACHE | NISCH 188/4885MTOR 3697/4885ADK 675/4885 |
| US-20240417383-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | NISCH 4175/4885MTOR 3100/4885ADK 691/4885 |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | NISCH 4175/4885MTOR 3100/4885ADK 691/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.